Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02101775
Title Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
City of Hope South Pasadena South Pasadena California 91030 United States Details
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 United States Details
Decatur Memorial Hospital Decatur Illinois 62526 United States Details
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
Mayo Clinic in Rochester Rochester Minnesota 55905 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232 United States Details
BCCA-Cancer Centre for the Southern Interior Kelowna British Columbia V1Y 5L3 Canada Details
BCCA-Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
London Regional Cancer Program London Ontario N6A 4L6 Canada Details
Ottawa Hospital and Cancer Center-General Campus Ottawa Ontario K1H 8L6 Canada Details
University Health Network Princess Margaret Cancer Center P2C Toronto Ontario M5G 2M9 Canada Details
University Health Network-Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
CHUM - Hopital Notre-Dame Montreal Quebec H2L 4M1 Canada Details
National University Hospital Singapore Singapore 119074 Singapore Details
*Shaded cells indicate that there was no data available from for the field